Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07560579 · ClinicalTrials.gov registry record · NA
Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity
A NA study, sponsored by Million Marker Wellness.
- Active
- Registry status
- NA
- Development phase
- 226
- Enrollment target
NCT07560579 is a NA study that is active but no longer recruiting, run by Million Marker Wellness. The registered enrollment target is 226 participants.
The verdict
NCT07560579, a NA study, is active but no longer recruiting, sponsored by Million Marker Wellness.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 226 participants
- Enrollment target
Study Summary
The goal of this study is to examine the relationship in individuals with overweight/obesity and endocrine disrupting chemical (EDC) exposure through a two-armed, randomized clinical trial. The main questions this study aims to answer are: 1. If MM's 12-week EDC intervention program (EDC testing and report-back, EDC reduction curriculum) can reduce weight? 2. If a 12-week validated digital weight loss program can reduce EDC exposures? 3. What is the effectiveness of the two interventions at reducing weight and urinary EDC metabolites? Participants will be assigned to one of these two arms. Participants will collect their urine and blood samples pre- and post-intervention, and will take a comprehensive exposure survey before sending back their samples. This exposure survey will ask about participant's weight loss literacy, environmental health literacy, product use, diet, and lifestyle behaviors.
Interventions
- DIAGNOSTIC_TEST Urinary EDC metabolite testing
- BEHAVIORAL Educational curriculum
- BEHAVIORAL Weight loss Application
- DIAGNOSTIC_TEST Siphox clinic biomarker test
- DIAGNOSTIC_TEST Weight loss reporting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2026-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07560579
The ClinicalTrials.gov registry entry for NCT07560579 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Million Marker Wellness, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Urinary EDC metabolite testing is the first listed.
NCT07560579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07560579 about?
NCT07560579 is a clinical study titled "Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity". The goal of this study is to examine the relationship in individuals with overweight/obesity and endocrine disrupting chemical (EDC) exposure through a two-armed, randomized clinical trial. The main questions this study aims to answer are: 1. If MM's 12-week EDC intervention program (EDC testing an...
What is the current status of trial NCT07560579?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 226 participants. The study started on 2025-08-18. Estimated completion is 2026-09.
What interventions are being tested in trial NCT07560579?
The interventions under investigation include: Urinary EDC metabolite testing (DIAGNOSTIC_TEST), Educational curriculum (BEHAVIORAL), Weight loss Application (BEHAVIORAL), Siphox clinic biomarker test (DIAGNOSTIC_TEST), Weight loss reporting (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07560579?
This trial is sponsored by Million Marker Wellness, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.